https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-28 / Clin. Dev. Immunol. 2011;2011:249281
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-28 / Clin. Dev. Immunol. 2011;2011:2492812011-09-28 00:00:002020-01-08 10:10:19Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-19 / Strahlenther Onkol 2011 Oct;187(10):619-252011-09-19 00:00:002011-09-19 00:00:00Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-842011-09-17 00:00:002019-02-15 08:52:16A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-14 / Clin. Dev. Immunol. 2011;2011:267539
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-14 / Clin. Dev. Immunol. 2011;2011:2675392011-09-14 00:00:002019-02-15 08:52:31Current immunotherapeutic approaches in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2011-09-01 17:28:532019-02-12 17:32:01Nobelpreis für Medizin 2011 für die Entdeckung grundlegender immunologischer Mechanismen
